Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc.AUPH · Entity 4463 | Chief Commercial Officer | August 06, 2024 | August 08, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aurinia Pharmaceuticals Inc.
Report date August 06, 2024 · Filed August 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 456,338 |
Reported balance
After 2024-08-06 transaction · row 1
1 source rowRow 1 · 2024-08-06 · Sale · Disposed 18,249 · Balance 456,338 F1: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units related to the August 1, 2022 grant. F2: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.29 to $5.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units related to the August 1, 2022 grant.
F2: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.29 to $5.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 06, 2024 Filed Aug 8, 2024 16:06 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 18,249 | $5.31 | $96,902.19 |
DisclosureSEC source: 0001600620-24-000093 · wk-form4_1723147608.xml · nonDerivative · entry 1 Habig Scott Michael · CIK 0001938159 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 456,338 F1 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units related to the August 1, 2022 grant. F2 · price: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.29 to $5.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| March 06, 2024 Filed Mar 7, 2024 16:42 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 17,777 | $5.60 | $99,551.20 |
DisclosureSEC source: 0001600620-24-000035 · wk-form4_1709847750.xml · nonDerivative · entry 1 Habig Scott Michael · CIK 0001938159 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 474,587 F1 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units related to the March 2, 2023 grant. F2 · price: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.475 to $5.755, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 16:33 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 15,867 | $5.48 | $86,951.16 |
DisclosureSEC source: 0001600620-24-000021 · wk-form4_1708637563.xml · nonDerivative · entry 2 Habig Scott Michael · CIK 0001938159 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 492,364 F2 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs granted on August 1, 2022 grant. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 16:33 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantCommon Stock | 195,512 | $0.00 | $0.00 |
DisclosureSEC source: 0001600620-24-000021 · wk-form4_1708637563.xml · nonDerivative · entry 1 Habig Scott Michael · CIK 0001938159 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 508,231 F1 · shares: Represents grant of Restricted Stock Units (RSUs) payable solely in common stock of the Issuer that vest in three (3) equal annual installments on the first, second and third anniversary of the grant date. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 16:28 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantCommon Stock | 170,188 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-006528 · wf-form4_167813810165437.xml · nonDerivative · entry 1 Habig Scott Michael · CIK 0001938159 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,719 F1 · shares: Represents grant of Restricted Stock Units (RSUs) payable solely in common stock of the Issuer that vest in three (3) equal annual installments on the first, second and third anniversary of the grant date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3 · balance_after: The reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 170,188 newly awarded RSUs and 137,531 RSUs previously reported in Table II, which vests in three (3) equal annual installments beginning August 1, 2023 and 5,000 shares of common stock. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 16:31 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | PurchaseCommon Stock | 5,000 | $5.02 | $25,075.00 |
DisclosureSEC source: 0001628280-22-029866 · wf-form4_166846148591533.xml · nonDerivative · entry 1 Habig Scott Michael · CIK 0001938159 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| August 01, 2022 Filed Aug 1, 2022 16:13 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantRestricted Stock Units · Derivative | 137,531 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-019949 · wf-form4_165938478001230.xml · derivative · entry 2 Habig Scott Michael · CIK 0001938159 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,531 Underlying: Common Shares · 137,531 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning August 1, 2023. F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning August 1, 2023. F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning August 1, 2023. Read SEC document |
| August 01, 2022 Filed Aug 1, 2022 16:13 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantStock Option (right to buy) · Derivative | 231,203 | $0.00 Strike: $8.18 | $0.00 |
DisclosureSEC source: 0001628280-22-019949 · wf-form4_165938478001230.xml · derivative · entry 1 Habig Scott Michael · CIK 0001938159 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,203 Underlying: Common Stock · 231,203 shares Expires 2032-08-01 F1 · derivative.exercise_date: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.